Science

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

Rahul Banerjee/X

Mar 4, 2025, 05:22

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, shared an article by Luciano J Costa, et al. on X:

“Yesterday I learned that teclistamab & talquetamab are approved in Mexico for triple-class exposed Multiple Myeloma regardless of lines of therapy Love this!

So much more practical and scientifically sound. Some day we’ll be able to ditch LOT, and it’ll be our LMIC colleagues leading the charge!”

Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.

Authors: Luciano J Costa, et al.

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

cancer fight against cancer Fred Hutchinson Cancer Center Global fight against cancer LMIC Luciano J Costa Mexico multiple myeloma OncoDaily Oncology Rahul Banerjee Talquetamab teclistamab University of Washington

20 Posts Not to Miss from ASCO 2025

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

15 Posts Not to Miss from the 4th Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025